Correction to “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS‐CoV‐2 Orf8 Viral Proteins”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
Topicsinterferon and immune responses · Chromatin Remodeling and Cancer · SARS-CoV-2 and COVID-19 Research
S. Lehrer and P. H. Rheinstein, “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS‐CoV‐2 Orf8 Viral Proteins,” Chronic Diseases and Translational Medicine 9 (2023): 263–265. https://doi.org/10.1002/cdt3.56.
The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article:
Conflicts of Interest
Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.